REGENERON PHARMACEUTICALS (REGN) Stock Fundamental Analysis
USA - NASDAQ:REGN - US75886F1075 - Common Stock
644.19 USD
+16.19 (+2.58%)
644.19 USD
0 (0%)
Overall REGN gets a fundamental rating of 6 out of 10. We evaluated REGN against 534 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making REGN a very profitable company, without any liquidiy or solvency issues. REGN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
REGN had positive earnings in the past year.
In the past year REGN had a positive cash flow from operations.
In the past 5 years REGN has always been profitable.
In the past 5 years REGN always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 11.40%, REGN belongs to the best of the industry, outperforming 94.19% of the companies in the same industry.
Looking at the Return On Equity, with a value of 14.79%, REGN belongs to the top of the industry, outperforming 94.57% of the companies in the same industry.
REGN has a better Return On Invested Capital (8.69%) than 93.82% of its industry peers.
The Average Return On Invested Capital over the past 3 years for REGN is below the industry average of 15.38%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.69% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
1.3 Margins
With an excellent Profit Margin value of 32.13%, REGN belongs to the best of the industry, outperforming 96.63% of the companies in the same industry.
In the last couple of years the Profit Margin of REGN has grown nicely.
Looking at the Operating Margin, with a value of 27.61%, REGN belongs to the top of the industry, outperforming 96.25% of the companies in the same industry.
In the last couple of years the Operating Margin of REGN has declined.
REGN's Gross Margin of 86.28% is amongst the best of the industry. REGN outperforms 88.58% of its industry peers.
In the last couple of years the Gross Margin of REGN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so REGN is still creating some value.
Compared to 1 year ago, REGN has about the same amount of shares outstanding.
Compared to 5 years ago, REGN has less shares outstanding
The debt/assets ratio for REGN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.64 indicates that REGN is not in any danger for bankruptcy at the moment.
REGN's Altman-Z score of 6.64 is fine compared to the rest of the industry. REGN outperforms 77.53% of its industry peers.
The Debt to FCF ratio of REGN is 0.70, which is an excellent value as it means it would take REGN, only 0.70 years of fcf income to pay off all of its debts.
REGN has a better Debt to FCF ratio (0.70) than 95.13% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that REGN is not too dependend on debt financing.
REGN has a Debt to Equity ratio of 0.09. This is in the lower half of the industry: REGN underperforms 63.11% of its industry peers.
Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 6.64 |
ROIC/WACC1.03
WACC8.47%
2.3 Liquidity
A Current Ratio of 4.06 indicates that REGN has no problem at all paying its short term obligations.
REGN has a Current ratio (4.06) which is in line with its industry peers.
A Quick Ratio of 3.51 indicates that REGN has no problem at all paying its short term obligations.
REGN has a Quick ratio (3.51) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.92%.
The Earnings Per Share has been growing by 13.12% on average over the past years. This is quite good.
REGN shows a small growth in Revenue. In the last year, the Revenue has grown by 2.89%.
REGN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.55% yearly.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
Based on estimates for the next years, REGN will show a small growth in Earnings Per Share. The EPS will grow by 6.65% on average per year.
The Revenue is expected to grow by 5.75% on average over the next years.
EPS Next Y-6.32%
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
EPS Next 5Y6.65%
Revenue Next Year-0.32%
Revenue Next 2Y2.42%
Revenue Next 3Y4.76%
Revenue Next 5Y5.75%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 14.31 indicates a correct valuation of REGN.
Based on the Price/Earnings ratio, REGN is valued cheaper than 96.82% of the companies in the same industry.
REGN is valuated rather cheaply when we compare the Price/Earnings ratio to 26.03, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 14.50 indicates a correct valuation of REGN.
REGN's Price/Forward Earnings ratio is rather cheap when compared to the industry. REGN is cheaper than 95.69% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.27. REGN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.31 | ||
| Fwd PE | 14.5 |
4.2 Price Multiples
REGN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. REGN is cheaper than 95.69% of the companies in the same industry.
REGN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. REGN is cheaper than 95.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.59 | ||
| EV/EBITDA | 12.31 |
4.3 Compensation for Growth
REGN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.09
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
5. Dividend
5.1 Amount
REGN has a yearly dividend return of 0.55%, which is pretty low.
REGN's Dividend Yield is rather good when compared to the industry average which is at 89.85. REGN pays more dividend than 98.31% of the companies in the same industry.
With a Dividend Yield of 0.55, REGN pays less dividend than the S&P500 average, which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.55% |
5.2 History
REGN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
644.19
+16.19 (+2.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners90.24%
Inst Owner Change0.19%
Ins Owners1.89%
Ins Owner Change0.18%
Market Cap68.28B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts80.59
Price Target747.8 (16.08%)
Short Float %2.87%
Short Ratio2.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.55% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)0.38%
PT rev (3m)-0.51%
EPS NQ rev (1m)-0.78%
EPS NQ rev (3m)3.7%
EPS NY rev (1m)0.53%
EPS NY rev (3m)10.86%
Revenue NQ rev (1m)0.55%
Revenue NQ rev (3m)4.52%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)3.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.31 | ||
| Fwd PE | 14.5 | ||
| P/S | 4.79 | ||
| P/FCF | 17.59 | ||
| P/OCF | 13.46 | ||
| P/B | 2.21 | ||
| P/tB | 2.31 | ||
| EV/EBITDA | 12.31 |
EPS(TTM)45.01
EY6.99%
EPS(NY)44.42
Fwd EY6.9%
FCF(TTM)36.62
FCFY5.68%
OCF(TTM)47.84
OCFY7.43%
SpS134.43
BVpS292.08
TBVpS279.05
PEG (NY)N/A
PEG (5Y)1.09
Graham Number543.87
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 11.99% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
ROICexc(3y)18.09%
ROICexc(5y)25.25%
ROICexgc(3y)19.06%
ROICexgc(5y)25.84%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 6.64 |
F-Score5
WACC8.47%
ROIC/WACC1.03
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-6.32%
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
EPS Next 5Y6.65%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year-0.32%
Revenue Next 2Y2.42%
Revenue Next 3Y4.76%
Revenue Next 5Y5.75%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-14.02%
EBIT Next 3Y4.25%
EBIT Next 5Y8.44%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 6 / 10 to REGN.
What is the valuation status for REGN stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 8 / 10.
Can you provide the expected EPS growth for REGN stock?
The Earnings per Share (EPS) of REGENERON PHARMACEUTICALS (REGN) is expected to decline by -6.32% in the next year.